Botulinum toxin-A for the treatment of neuralgia: a systematic review and meta-analysis

Fan Meng
Ke Peng
Jian-Ping Yang
Fu-Hai Ji
Fan Xia
Xiao-Wen Meng

Department of anesthesiology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Aim: This meta-analysis was performed to evaluate the efficacy and safety of botulinum toxin-A (BTX-A) for the treatment of neuralgia.

Methods: We searched PubMed, EMBASE, and Cochrane databases to identify randomized controlled trials (RCTs) comparing BTX-A treatment with saline for alleviating neuropathic pain. Primary outcome measures were pain scores up to 24 weeks after treatment. Secondary outcomes were hours of sleep, Short Form-36 (SF-36) life quality questionnaire, and adverse events. We used Review Manager 5.3 for the data analyses.

Results: Twelve RCTs were included (n=495). Pain scores in the BTX-A group were significantly lower compared to the saline group at 4 weeks (mean difference [MD] = −1.64, 95% CI [−3.21, −0.07], P=0.04), 12 weeks (MD = −1.49, 95% CI [−2.05, −0.93], P<0.00001), and 24 weeks (MD = −1.61, 95% CI [−2.81, −0.40], P=0.009). There were no significant differences in hours of sleep, SF-36 questionnaire, or the incidence of injection pain or hematoma between the two groups. No serious adverse events associated with BTX-A were noted. Fourteen out of 108 patients (12.9%) with trigeminal neuralgia experienced mild facial asymmetry after the BTX-A treatment.

Conclusion: Based on the current evidence, BTX-A may be an effective and safe option for the treatment of neuralgia. Due to the limited number of patients included in this meta-analysis, more trials are still needed to confirm these results.

Keywords: botulinum toxin, neuralgia, neuropathic pain, meta-analysis

Introduction

Clinical examples of neuropathic pain include trigeminal neuralgia, diabetic neuropathic pain, postherpetic neuralgia, and postsurgical neuralgia. Of note, neuropathic pain is often difficult to treat and can lead to anxiety and depression, which seriously compromise patients’ quality of life.1

Over the years, the pharmacotherapies used for neuropathic pain include pregabalin, gabapentin, antidepressants, anticonvulsants, carbamazepine, lamotrigine, opioids, and so on. However, the evidence for these interventions is often inconclusive.2 In addition, side effects associated with the medications such as dizziness, ataxia, nausea, vomiting, somnolence, and rash can be troublesome and debilitating.3

Botulinum toxin-A (BTX-A), a potent neurotoxin produced by Clostridium botulinum, blocks acetylcholine release at neuromuscular junctions and causes muscle relaxation.4 Animal studies have indicated several possible mechanisms for the analgesic effects of BTX-A: 1) it inhibits the release of pain mediators from both motor and...
sensory neurons, and blocks the release of calcitonin gene-related peptide and other neuropeptide; 2) it reduces chronic inflammation and acute injury by inhibiting neurotransmitter release; and 3) it deactivates the sodium channel in central nerve system neurons.

Recent studies have shown promising analgesic effects of BTX-A on postherpetic neuralgia, trigeminal neuralgia, and other types of neuralgia. However, sample sizes of the previous studies are relatively small. In this systematic review and meta-analysis, we aim to evaluate the safety and efficacy of BTX-A in the treatment of neuralgia based on the evidence from randomized controlled trials (RCTs).

Methods

Search strategy
This study adheres to the guidelines of PRISMA statement and the recommendations of the Cochrane Collaboration (Table S1). FM and KP independently searched PubMed, EMBASE, and Cochrane databases without language or publication date restrictions. The search strategies are shown in Table S2. Additional articles in the references and reviews were manually searched.

Inclusion criteria
The studies that fulfilled the following criteria were included in the meta-analysis:
1. Study design: RCT;
2. participants: adult patients with neuralgia;
3. interventions: use of BTX-A compared to saline;
4. outcome measures: pain scores, hours of sleep, the Short Form-36 (SF-36) life quality questionnaire, and adverse events.

Exclusion criteria
The studies that met the following criteria were excluded:
1. Insufficient data;
2. case reports, reviews, abstracts, editorials, or letters;
3. in vitro or animal experiments.

Data extraction
FM and KP independently screened the articles and extracted the following data: first author, publication date, country, sample size, groups and interventions, dose of BTX-A, and main outcomes. Any disagreement over study selection or data extraction was resolved by group discussion.

Primary and secondary outcomes
The primary outcome was the pain scores in visual analog scale (VAS) or numerical rating scale (NRS) at 4, 12, and 24 weeks after treatment (0 = no pain, 10 = maximum pain imaginable). The secondary outcomes were changes in hours of sleep and SF-36 at 12 weeks, and adverse events associated with the procedure.

Quality assessment
FM and KP independently assessed the risk of bias of the included studies using the Cochrane Collaboration tool. This tool includes seven areas: the generation of random sequence, allocation concealment, participant blind method, result evaluation blind method, data of incomplete results, report of selected results, and other potential sources of bias. For each area, the risk was rated as “high”, “low”, or “unclear”. Any disagreement over quality assessment was resolved by group discussion.

Statistical analysis
Data analyses were performed using Review Manager 5.3 (The Cochrane Collaboration, Copenhagen, Denmark). For continuous variables, mean differences (MDs) with 95% CIs were calculated, and for dichotomous variables, ORs with 95% CIs were calculated. I² was used to evaluate heterogeneity, with I² > 50% indicating significant heterogeneity. In view of the clinical heterogeneity, we applied a random-effects model in this meta-analysis. A P-value of <0.05 denoted statistical significance.

Results

Literature search and study characteristics
The PRISMA flow diagram is shown in Figure 1. Of the 211 articles initially identified, 56 duplicates were excluded. After reviewing the titles and abstracts, 38 articles remained. Finally, 12 RCTs were included in this meta-analysis. The study characteristics are presented in Table 1. A total of 495 patients (266 in the BTX-A group and 229 in the saline group) were followed up for 8–24 weeks after the treatment.

Risk-of-bias assessment
The risk-of-bias assessment is summarized in Figure 2. All trials were randomized and double-blind. Two studies did not detail the random sequence generation, and two did not adequately report the allocation concealment.
The efficacy and safety of BTX-A for the treatment of neuralgia

Pain scores
As shown in Figure 3, the BTX-A group had significantly lower pain scores than the saline group at 4 weeks (MD = –1.64, 95% CI [–3.21, –0.07], *P* = 0.04), 12 weeks (MD = –1.49, 95% CI [–2.05, –0.93], *P* < 0.00001), and 24 weeks (MD = –1.61, 95% CI [–2.81, –0.40], *P* = 0.009).

Secondary outcomes
As shown in Figure 4, there were no significant differences in changes in hours of sleep (MD = 0.37, 95% CI [–0.28, 1.02], *P* = 0.27) or SF-36 scores (MD = 52.50, 95% CI [–35.88, 140.87], *P* = 0.24) at 12 weeks between the two groups.

The incidences of adverse events are presented in Figure 5. No significant difference in injection pain (OR = 0.89, 95% CI [0.48, 1.64], *P* = 0.71) or hematoma (OR = 0.93, 95% CI [0.24, 3.67], *P* = 0.92) was found between the groups. However, 14 out of 108 (12.9%) patients with trigeminal neuralgia reported mild facial asymmetry after BTX-A treatment (OR = 7.5, 95% CI [1.64, 34.21], *P* = 0.009).

Discussion
In this study, we comprehensively summarized the current evidence and found lower pain scores up to 24 weeks after BTX-A treatment compared with saline in patients with neuropathic pain. Additionally, there were no serious adverse events associated with BTX-A injections.

Recently, there are several published meta-analyses regarding the use of BTX-A in neuralgia. Morra et al. evaluated BTX-A therapy in trigeminal neuralgia, suggesting that BTX-A may be an effective and safe option. However, only four RCTs were included in their study. Shackleton et al. analyzed six RCTs and showed that BTX-A alleviated trigeminal neuralgia and postherpetic neuralgia. Another meta-analysis by Lakhan et al. indicated that BTX-A treatment improved diabetic neuropathic pain with the results of only two trials. In our study, we included 12 RCTs to determine the effects of BTX-A treatment at three different time points (4, 12, and 24 weeks). Our results suggested that BTX-A treatment could relieve neuropathic pain both in the short term and in the long run.
<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Groups and interventions</th>
<th>n</th>
<th>Injection route</th>
<th>Cause of pain</th>
<th>Follow-up (weeks)</th>
<th>Main outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apalla et al (2013)²</td>
<td>Greece</td>
<td>1. 100 U BTX-A 2. 0.9% saline</td>
<td>15</td>
<td>Subcutaneous</td>
<td>Postherpetic neuralgia</td>
<td>20</td>
<td>Pain VAS scores, sleep scores, injection pain</td>
</tr>
<tr>
<td>Attal et al (2016)³</td>
<td>France</td>
<td>1. Up to 300 U BTX-A 2. 0.9% saline</td>
<td>34</td>
<td>Subcutaneous</td>
<td>Peripheral neuropathic pain</td>
<td>24</td>
<td>Pain NRS scores, NPSI, HAD, quality of sleep, hours of sleep, PGIC, injection pain</td>
</tr>
<tr>
<td>Finlayson et al (2011)⁴</td>
<td>Canada</td>
<td>1. 75 U BTX-A 2. 0.9% saline</td>
<td>20</td>
<td>Intramuscular</td>
<td>Thoracic outlet syndrome</td>
<td>24</td>
<td>Pain VAS scores, DASH, SF-36 questionnaire</td>
</tr>
<tr>
<td>Fishman et al (2017)⁵</td>
<td>US</td>
<td>1. 300 U BTX-A 2. 0.9% saline</td>
<td>28</td>
<td>Intramuscular</td>
<td>Piriformis syndrome</td>
<td>12</td>
<td>Pain VAS scores, posterior tibial or fibular H-reflexes in flexion, injection pain</td>
</tr>
<tr>
<td>Finlayson et al (2011)⁶</td>
<td>Canada</td>
<td>1. 75 U BTX-A 2. 0.9% saline</td>
<td>18</td>
<td>Subcutaneous</td>
<td>Thoracic outlet syndrome</td>
<td>12</td>
<td>Pain VAS scores, quality of life, injection pain</td>
</tr>
<tr>
<td>Han et al (2016)⁷</td>
<td>South Korea</td>
<td>1. 200 U BTX-A 2. 0.9% saline</td>
<td>20</td>
<td>Subcutaneous</td>
<td>Spinal cord injury</td>
<td>8</td>
<td>Pain VAS scores, SF-MPQ, quality of life, injection pain</td>
</tr>
<tr>
<td>Ranoux et al (2008)⁸</td>
<td>France</td>
<td>1. Up to 200 U BTX-A 2. 0.9% saline</td>
<td>15</td>
<td>Intradermal</td>
<td>Chronic neuropathic pain</td>
<td>24</td>
<td>Pain VAS scores, NPSI, BPI, HAD, PGIC, injection pain</td>
</tr>
<tr>
<td>Shehata et al (2013)⁹</td>
<td>Egypt</td>
<td>1. 100 U BTX-A 2. 0.9% saline</td>
<td>10</td>
<td>Subcutaneous</td>
<td>Trigeminal neuralgia</td>
<td>12</td>
<td>Pain VAS scores, paroxysms frequency, quality of life, facial asymmetry, hematoma, itching, injection pain</td>
</tr>
<tr>
<td>Wu et al (2012)¹⁰</td>
<td>China</td>
<td>1. 75 U BTX-A 2. 0.9% saline</td>
<td>22</td>
<td>Intradermal and/or submucosal</td>
<td>Trigeminal neuralgia</td>
<td>13</td>
<td>Pain VAS scores, PGIC, paroxysms frequency, facial asymmetry, transient edema</td>
</tr>
<tr>
<td>Xiao et al (2010)¹¹</td>
<td>China</td>
<td>1. 100 U BTX-A 2. 0.9% saline</td>
<td>20</td>
<td>Subcutaneous</td>
<td>Postherpetic neuralgia</td>
<td>12</td>
<td>Pain VAS scores, quality of life, hours of sleep, opioid usage, injection pain</td>
</tr>
<tr>
<td>Yuan et al (2009)¹²</td>
<td>China</td>
<td>1. 50 U BTX-A 2. 0.9% saline</td>
<td>9</td>
<td>Intradermal</td>
<td>Diabetic neuropathic pain</td>
<td>12</td>
<td>Pain VAS scores, CPSQI, SF-36 questionnaire</td>
</tr>
<tr>
<td>Zhang et al (2014)¹³</td>
<td>China</td>
<td>1. 25 U BTX-A 2. 75 U BTX-A 3. 0.9% saline</td>
<td>25</td>
<td>Intradermal and/or submucosal</td>
<td>Trigeminal neuralgia</td>
<td>9</td>
<td>Pain VAS scores, PGIC, paroxysms frequency, proportion of responders, facial asymmetry, transient edema</td>
</tr>
<tr>
<td>Zúñiga et al (2013)¹⁴</td>
<td>Argentina</td>
<td>1. 50 U BTX-A 2. 0.9% saline</td>
<td>20</td>
<td>Subcutaneously</td>
<td>Trigeminal neuralgia</td>
<td>12</td>
<td>Pain VAS scores, functional impact scores, SF-36 questionnaire, paroxysms, hematoma, facial asymmetry</td>
</tr>
</tbody>
</table>

**Abbreviations:** BPI, Brief Pain Inventory; BTX-A, botulinum toxin-A; CPSQI, Chinese version of the Pittsburgh Sleep Quality Index; DASH, Disabilities of the Arm, Shoulder, and Hand; HAD, Hospital Anxiety and Depression; NPSI, Neuropathic Pain Symptom Inventory; NRS, numerical rating scale; PGIC, Patient Global Impression of Change; SF-36, Short-Form 36; SF-MPQ, Short-Form McGill Pain Questionnaire; VAS, visual analog scale.
This meta-analysis included studies of trigeminal neuralgia, postherpetic neuralgia, diabetic neuropathic pain, and other types of chronic neuropathic pain (peripheral neuropathic pain, thoracic outlet syndrome, piriformis syndrome, and spinal cord injury). Of these, piriformis syndrome is a myofascial condition caused by a nerve entrapment where BTX-A injections reduce the pain by relieving muscle spasms. In cases of other conditions responsible for neuropathic pain including occipital neuralgia, carpal tunnel syndrome, and phantom limb pain, BTX-A was also reported to help reduce the pain. For six patients with occipital neuralgia, BTX-A improved the sharp/shooting type of pain. One report showed that BTX-A relieved symptoms in five women with carpal tunnel syndrome suggesting the long-lasting antinociceptive effects of BTX-A, while another study found it did not provide significant relief of carpal tunnel syndrome symptoms. For amputee patients, BTX-A resulted in improvement of residual limb pain and pain tolerance. However, no RCT for these types of neuropathic pain could be identified through our literature search.

The injection dose of BTX-A varied among the included studies. Most patients received a dose of 100–200 U, subcutaneously, intradermally, or intramuscularly. For patients with postherpetic neuralgia and trigeminal neuralgia, subcutaneous or intradermal injections of BTX-A were used, which mainly acted by blocking peripheral nerve endings. For other types of chronic neuropathic pain, intramuscular injections were carried out to help relieve muscle spasms.
### Figure 3

**BTX-A vs saline for the treatment of neuralgia: pain scores at 4, 12, and 24 weeks.**

| Study or Subgroup | Mean SD Total Mean SD Total Weight IV, Random, 95% CI Mean Difference IV, Random, 95% CI |
|-------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                   | BTX-A            | Saline          |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Apall 2013        | 3.9 ± 0.98      | 15              | 8.2 ± 0.89       | 15              | 18.3%            | -4.30 [-4.94, -3.66] |                   |                   |                   |                   |                   |                   |                   |                   |
| Attal 2016        | 5.3 ± 2.3       | 34              | 6.1 ± 1.7        | 32              | 17.6%            | -0.80 [-1.07, 0.17] |                   |                   |                   |                   |                   |                   |                   |                   |
| Han 2016          | 6.65 ± 2.07     | 20              | 7.45 ± 1.5       | 20              | 17.2%            | -0.80 [-1.65, 0.05] |                   |                   |                   |                   |                   |                   |                   |                   |
| Ranoux 2009       | 4.5 ± 3.0       | 15              | 5.4 ± 2.2        | 14              | 14.6%            | -0.90 [-2.81, 1.01] |                   |                   |                   |                   |                   |                   |                   |                   |
| Yuan 2009         | 4.2 ± 1.3       | 9               | 5.9 ± 1.3        | 9               | 17%              | -1.70 [-2.90, -0.50] |                   |                   |                   |                   |                   |                   |                   |                   |
| Zúñiga 2013       | 5.1 ± 2.8       | 20              | 6.1 ± 2.8        | 16              | 15.0%            | -1.00 [-2.84, 0.84] |                   |                   |                   |                   |                   |                   |                   |                   |
| Subtotal (95% CI) | 113             | 106             | 100.0%           | -1.64 [-3.21, -0.07] |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Heterogeneity: Tau² = 3.41; Chi² = 57.83, df = 5 (P < 0.00001); I² = 91% |

Test for overall effect: Z = 2.04 (P = 0.04)

### Figure 4

**BTX-A vs saline for the treatment of neuralgia: (A) changes in hours of sleep at 3 months; and (B) changes in Short Form-36 questionnaires at 12 weeks.**

**Abbreviations:** BTX-A, botulinum toxin-A; IV, inverse variance.

#### A

| Study or Subgroup | Mean SD Total Mean SD Total Weight IV, Random, 95% CI Mean Difference IV, Random, 95% CI |
|-------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                   | BTX-A            | Saline          |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Attal 2016        | 0.7 ± 1.75      | 34              | -0.1 ± 1.61      | 32              | 60.8%            | 0.10 [-3.71, 0.91] |                   |                   |                   |                   |                   |                   |                   |                   |
| Xiao 2010         | 2.78 ± 1.61     | 20              | 2 ± 1.68         | 20              | 39.2%            | 0.76 [-0.24, 1.80] |                   |                   |                   |                   |                   |                   |                   |                   |
| Total (95% CI)    | 54              | 52              | 100.0%           | 0.57 [-0.28, 1.02] |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Heterogeneity: Tau² = 0.01; Chi² = 1.05, df = 1 (P = 0.31); I² = 4% |

Test for overall effect: Z = 1.10 (P = 0.27)

#### B

| Study or Subgroup | Mean SD Total Mean SD Total Weight IV, Random, 95% CI Mean Difference IV, Random, 95% CI |
|-------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                   | BTX-A            | Saline          |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Finlayson 2011    | 17 ± 560        | 20              | -54 ± 560        | 18              | 6.3%             | 71.00 [282.26, 424.26] |                   |                   |                   |                   |                   |                   |                   |                   |
| Yuan 2009         | 31.8 ± 171.8    | 9               | 60 ± 177.3       | 9               | 30.6%            | -28.20 [-189.40, 133.09] |                   |                   |                   |                   |                   |                   |                   |                   |
| Zúñiga 2013       | 87.5 ± 192.7    | 20              | -12 ± 146.1      | 16              | 63.7%            | 83.70 [22.01, 199.41] |                   |                   |                   |                   |                   |                   |                   |                   |
| Total (95% CI)    | 49              | 43              | 100.0%           | 62.50 [-35.88, 140.87] |                   |                   |                   |                   |                   |                   |                   |                   |                   |
| Heterogeneity: Tau² = 0.00; Chi² = 1.35, df = 2 (P = 0.52); I² = 0% |

Test for overall effect: Z = 1.16 (P = 0.24)

---

**Figure 4** BTX-A vs saline for the treatment of neuralgia: (A) changes in hours of sleep at 3 months; and (B) changes in Short Form-36 questionnaires at 12 weeks.

**Abbreviations:** BTX-A, botulinum toxin-A; IV, inverse variance.
In our study, BTX-A injections failed to improve hours of sleep or quality of life surveyed by SF-36 questionnaire in patients with neuropathic pain. These results did not parallel with the improvement of pain scores after BTX-A treatment. Apart from the limited number of studies included for these two measurements, the complexity of contributory factors in life quality should also be noted for this inconsistency.

Regarding the safety of BTX-A, no significant adverse effects were noted. Overall, 59 out of 142 (41.5%) patients in the BTX-A group and 59 out of 137 (43.1%) patients in the saline group reported injection pain. Besides, there were seven out of 128 (5.5%) and seven out of 92 (7.6%) patients who exhibited hematoma at injection site. Out of 108 patients with trigeminal neuralgia, 14 (12.9%) developed mild facial asymmetry after the BTX-A treatment. However, this symptom was self-limited without the need for other interventions. Compared to trigeminal neuralgia attacks, patients generally reported this complication tolerable.

**Limitations**

There are several limitations of this study. First, the current literature was limited, and the sample size was relatively small. Second, we were not able to explore the potential publication bias through funnel plot due to the insufficient number of studies. Third, some studies suggested that NRS and VAS for pain are not necessarily interchangeable in some clinical situations; thus, potential bias may exist by pooling and analyzing these data. Next, heterogeneity exists for some of the results, so they should be interpreted with caution. Last, our study was underpowered to detect any effect of BTX-A on patients’ quality of life.

---

**Figure 5** BTX-A vs saline for the treatment of neuralgia: adverse events.

**Abbreviations:** BTX-A, botulinum toxin-A; M-H, Mantel–Haenszel.
Conclusion
This study suggests that BTX-A may be a good choice for the treatment of neuralgia. More well-designed RCTs with large sample sizes are needed to confirm these findings.

Acknowledgments
This work was supported, in part, by grants from the National Natural Science Foundation of China (81601659 to KP, 81471835 and 81671880 to FHJ) and the Jiangsu Provincial Medical Youth Talents Program (QNRC2016741 to KP).

Disclosure
The authors report no conflicts of interest in this work.

References